NCT04520659: Evaluating the Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine, LID/ΔM2-2/1030s, in RSV-Seronegative Infants and Children 6 to 24 Months of Age |
|
|
| Completed | 1 | 81 | US | RSV LID/ΔM2-2/1030s, Placebo | National Institute of Allergy and Infectious Diseases (NIAID), Sanofi Pasteur, a Sanofi Company | RSV Infection | 04/24 | 04/24 | | |
NCT03924219: CMV T Cell Immunity in Pediatric Solid Organ Transplant Recipients |
|
|
| Active, not recruiting | N/A | 120 | US | CMV T cell Immunity Assay | Vanderbilt University Medical Center, ViraCor Laboratories | Heart Transplant Infection, Kidney Transplant Infection, Liver Transplant Infection, CMV | 08/24 | 07/25 | | |
